Optimal Dose of Pituitrin in Laparoscopic Uterine Myomectomy: a
Prospective, Double-Blinded, Randomized Controlled Trial
Abstract
Objective: To determine the optimal effective dose pituitrin in
laparoscopic myomectomy for uterine leiomyoma. Design: Prospective,
double-blinded, randomized controlled trial. Setting: A tertiary women’s
hospital in China. Population: A total of 118 women who underwent
laparoscopic myomectomy. Methods: Women were randomly divided into four
groups to receive 0, 2, 4, or 6 units of pituitrin in the leiomyoma
(groups 0U, 2U, 4U, and 6U, respectively). Main outcome measures: Rate
of satisfactory surgical field, hemodynamic changes, total surgical time
and blood loss were recorded. Results: The rate of sastisfactory
surgical field was 6.7%, 72.4%, 89.7% and 93.3% in groups 0U, 2U,
4U, and 6U, respectively; it was higher in groups 2U, 4U, and 6U than
group 0U, but there were no significant differences among the groups 2U,
4U, and 6U. The blood loss was higher in group 0U than that in groups
2U, 4U, and 6U (). Pituitrin was associated with a transient decrease in
blood pressures and increase in heart rate in a dose-dependent fashion,
with more pronounced changes in groups 4U and 6U and these groups also
required higher amount of vasoactive drug to correct hemodynamic changes
(p<0.05). Conclusions: Use low-dose pituitrin (2 units)
provides a satisfactory surgical field with minimal hemodynamic changes.